Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease

Neurological Sciences

Volumn 23, Issue SUPPL. 2, 2002, Pages

  Arabia, G ^a   Zappia, M ^c   Bosco, D ^b   Crescibene, L ^b   Bagala A ^b   Bastone, L ^b   Caracciolo, M ^b   Scornaienghi, M ^b   Quattrone, A ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; SEX DIFFERENCE;

ADMINISTRATION, ORAL; AGED; BODY WEIGHT; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEX FACTORS;

EID: 0036757042     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720200066     Document Type: Article

References (7)

1. Tanner CM, Aston DA (2000) Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol 13:427-430
2. Rascol O (1999) L-Dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacological approach. Mov Disord 14[Suppl 1]:19-32
3. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 32:185-209
4. Oliveri RL, Annesi G, Zappia M et al (1999) Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53:1425-1430
5. Baruzzi A, Contin M, Albani F, Riva R (1986) Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 375:165-169
6. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39:37-45
7. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC (1999) Gender differences in Parkinson's disease. Clin Neuropharmacol 21:118-121